Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

The bacterial toxin RelE cleaves mRNA in the ribosomal A site. Although it shares a global fold with other microbial RNases, the active site contains several positively charged residues instead of histidines and glutamates that are typical of ribonucleases. The pH dependences of wild-type and mutant RelE indicate it uses general acid-base catalysis, but either the general acid (proposed to be R81) or the general base must have a substantially downshifted p. However, which group is shifted cannot be determined using available structural and biochemical data. Here, we use a phosphorothiolate at the scissile phosphate to remove the need for a general acid. We show this modification rescues nearly all of the defect of the R81A mutation, supporting R81 as the general acid. We also find that the observed p of the general base is dependent on the charge of the side chain at position 81. This indicates that positive charge in the active site contributes to a general base p downshifted by more than 5 units. Although this modestly reduces the effectiveness of general acid-base catalysis, it is strongly supplemented by the role of the positive charge in stabilizing the transition state for cleavage. Furthermore, we show that the ribosome is required for cleavage but not binding of mRNA by RelE. Ribosome functional groups do not directly contact the scissile phosphate, indicating that positioning and charge interactions dominate RelE catalysis. The unusual RelE active site catalyzes phosphoryl transfer at a rate comparable to those of similar enzymes, but in a ribosome-dependent fashion.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7260706PMC
http://dx.doi.org/10.1021/acs.biochem.9b01047DOI Listing

Publication Analysis

Top Keywords

active site
16
general base
16
general acid
12
general
9
positively charged
8
bacterial toxin
8
toxin rele
8
general acid-base
8
acid-base catalysis
8
r81 general
8

Similar Publications

Structure-Activity Relationships of 3-Hydroxypropanamidines (HPAs) with Potent In Vivo Antimalarial Activity.

J Med Chem

September 2025

Faculty of Mathematics and Natural Sciences, Institute of Pharmaceutical and Medicinal Chemistry, Heinrich Heine University Düsseldorf, 40225 Düsseldorf, Germany.

New treatment strategies are required to combat the spread of drug-resistant malaria. The synthesis and preclinical evaluation of novel 3-hydroxy-propanamidines (HPAs), with modifications of the phenanthrene and the 4-fluorobenzamidine moieties, has yielded several analogs exhibiting excellent in vitro growth inhibition of drug-sensitive or resistant fresh clinical isolates and culture-adapted strains. No cytotoxicity in the human HepG2 cell line was observed, demonstrating notable parasite selectivity.

View Article and Find Full Text PDF

d-2-Hydroxyglutarate dehydrogenase (D2HGDH) has recently received considerable attention due to the involvement of d-2-hydroxyglutarate in various medical conditions. This enzyme has been reported to diverge in substrate scope depending on whether its source is prokaryotic or eukaryotic. The D2HGDH from , D2HGDH, is of particular interest due to its requirement for survival via the l-serine biosynthesis pathway and its potential use as a therapeutic target against the bacterium.

View Article and Find Full Text PDF

Tailoring Active Sites in Amorphous NiFe-MOFs through Pyridine Ligand Coordination for Enhanced Oxygen Evolution Performance.

ACS Appl Mater Interfaces

September 2025

Jiangsu Key Laboratory of Advanced Catalytic Materials and Technology, Advanced Catalysis and Green Manufacturing Collaborative Innovation Center, Changzhou University, Changzhou 213164, P. R. China.

The development of high-performance, cost-effective non-noble metal catalysts for the oxygen evolution reaction (OER) is critical to advancing sustainable hydrogen production via water electrolysis. Herein, we report a facile and mild strategy for synthesizing amorphous bimetallic organic framework materials (NiFe-MOFs) using pyridine-modified threonine (l-PyThr) as an organic ligand. The optimized NiFe-PyThr-4:1 catalyst exhibits remarkable OER activity, requiring low overpotentials of only 162 and 222 mV to achieve current densities of 10 and 100 mA cm, respectively, along with a small Tafel slope of 34.

View Article and Find Full Text PDF

The anaerobic glycyl radical enzyme choline trimethylamine-lyase (CutC) is produced by multiple bacterial species in the human gut microbiome and catalyzes the conversion of choline to trimethylamine (TMA) and acetaldehyde. CutC has emerged as a promising therapeutic target due to its role in producing TMA, which is subsequently oxidized in the liver to form trimethylamine--oxide (TMAO). Elevated TMAO levels are associated with several human diseases, including atherosclerosis and other cardiovascular disorders─a leading cause of mortality worldwide.

View Article and Find Full Text PDF

Background And Objectives: Deucravacitinib, a first-in-class, oral, selective, allosteric tyrosine kinase 2 inhibitor, demonstrated efficacy across the primary endpoint and all key secondary endpoints in the phase 2 PAISLEY SLE trial in patients with active systemic lupus erythematosus (SLE). Here, we describe 2 phase 3 trials [POETYK SLE-1 (NCT05617677), POETYK SLE-2 (NCT05620407)] which will assess the efficacy and safety of deucravacitinib in patients with active SLE. These phase 3 trials have been designed to replicate the successful elements of the phase 2 trial, including its glucocorticoid-tapering strategy and disease activity adjudication.

View Article and Find Full Text PDF